Prothena Corporation PLC
PRTA
View Detailed Chart
9.540USD
-0.150-1.55%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
513.54MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.55%
5 Days
+3.58%
1 Month
-8.53%
6 Months
+56.91%
Year to Date
-31.12%
1 Year
-36.99%
View Detailed Chart
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2025-12-26Key Insights
Prothena Corporation PLC's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 131/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 20.33.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Hold
Current Rating
20.333
Target Price
+89.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 150.73% year-on-year.
Overvalued
The company’s latest PE is -1.83, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.85M shares, decreasing 26.64% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 3.67K shares of this stock.
Prothena Corporation PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prothena Corporation PLC Info
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Ticker SymbolPRTA
CompanyProthena Corporation PLC
CEOKinney (Gene G)
Websitehttps://www.prothena.com/
FAQs
What is the current price of Prothena Corporation PLC (PRTA)?
The current price of Prothena Corporation PLC (PRTA) is 9.540.
What is the symbol of Prothena Corporation PLC?
The ticker symbol of Prothena Corporation PLC is PRTA.
What is the 52-week high of Prothena Corporation PLC?
The 52-week high of Prothena Corporation PLC is 16.665.
What is the 52-week low of Prothena Corporation PLC?
The 52-week low of Prothena Corporation PLC is 4.320.
What is the market capitalization of Prothena Corporation PLC?
The market capitalization of Prothena Corporation PLC is 513.54M.
What is the net income of Prothena Corporation PLC?
The net income of Prothena Corporation PLC is -122.31M.
Is Prothena Corporation PLC (PRTA) currently rated as Buy, Hold, or Sell?
According to analysts, Prothena Corporation PLC (PRTA) has an overall rating of Hold, with a price target of 20.333.
What is the Earnings Per Share (EPS TTM) of Prothena Corporation PLC (PRTA)?
The Earnings Per Share (EPS TTM) of Prothena Corporation PLC (PRTA) is -5.211.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
